Literature DB >> 8406370

Contribution of sinusoidal endothelial liver cells to liver fibrosis: expression of transforming growth factor-beta 1 receptors and modulation of plasmin-generating enzymes by transforming growth factor-beta 1.

H Rieder1, T Armbrust, K H Meyer zum Büschenfelde, G Ramadori.   

Abstract

Transforming growth factor-beta 1 is an important cytokine in the pathophysiology of liver fibrosis, stimulating the production of extracellular matrix. Whether this cytokine can also control the degradation of matrix proteins in liver cells has not been investigated. Because plasmin is an important protease for the degradation of matrix glycoproteins, we investigated whether sinusoidal endothelial liver cells could contribute to fibrosing liver disease through the modulation of plasmin-generating enzymes in response to transforming growth factor-beta 1. Sinusoidal endothelial cells from guinea pig liver were investigated in pure monolayer culture. Using 125I-labelled transforming growth factor-beta, we demonstrated high-affinity binding sites on sinusoidal endothelial cells at a density of 9.3 x 10(2) per cell, and a dissociation constant of about 5.5 x 10(-11) mol/L. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed the known three classes of membrane receptors for transforming growth factor-beta. Using biosynthetic labeling of proteins with 35S-methionine, immunoprecipitation and sodium dodecyl sulfate-polyacrylamide gel electrophoresis, we showed that sinusoidal endothelial cells produce and secrete plasminogen activator inhibitor type 1 from the beginning of culture. Treatment of confluent cell cultures for 24 hr with transforming growth factor-beta 1 increased synthesis and release of plasminogen activator inhibitor type 1. The response was almost maximal at a concentration of 1 ng transforming growth factor-beta/ml and paralleled the increased synthesis of fibronectin. On reverse fibrin autography we proved that transforming growth factor-beta 1 stimulated the release of functionally active plasminogen activator inhibitor type 1.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8406370     DOI: 10.1002/hep.1840180427

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  7 in total

1.  Role of transforming growth factor-[beta]1 in inhibiting endothelial cell proliferation in experimental alcoholic liver disease.

Authors:  A A Nanji; S R Tahan; M Golding; S Khwaja; A Rahemtulla; E N Lalani
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

2.  In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis.

Authors:  J George; D Roulot; V E Koteliansky; D M Bissell
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

3.  Co-administration of cyclosporine an alleviates thioacetamide-induced liver injury.

Authors:  Sabrina Fan; Ching-Feng Weng
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

4.  Inhibition of VEGF- and NO-dependent angiogenesis does not impair liver regeneration.

Authors:  U Shergill; A Das; D Langer; Rs Adluri; N Maulik; V H Shah
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-05       Impact factor: 3.619

Review 5.  Role of ethanol in the regulation of hepatic stellate cell function.

Authors:  Jian-Hua Wang; Robert-G Batey; Jacob George
Journal:  World J Gastroenterol       Date:  2006-11-21       Impact factor: 5.742

6.  Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation.

Authors:  D M Bissell; S S Wang; W R Jarnagin; F J Roll
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

7.  Epigallocatechin 3-gallate ameliorates bile duct ligation induced liver injury in mice by modulation of mitochondrial oxidative stress and inflammation.

Authors:  Kezhen Shen; Xiaowen Feng; Rong Su; Haiyang Xie; Lin Zhou; Shusen Zheng
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.